patritumab
daiichi sankyo
['patritumab', 'breast', 'tnbc']
patritumab deruxtecan (her3 adc) in metastatic breast cancer that was her3+ (113 hr+, 53 tnbc, 14 her2+) orr hr+ 30%, 23% tnbc, 43% her2+ her3 expression dynamic. 6.6% ild #asco22 
Chief, Division of Breast Oncology @DanaFarber
Tennis fan
Mother of two teenage girls